Ovarian Cancer Clinical Trial

Intra-op Detection of Occult Ovarian Carcinoma Using a Folate-Alpha Receptor Specific Fluorescent Ligand

Summary

Prognosis for many carcinomas, including ovarian carcinoma, is dependent on a complete surgical resection, also known as a R0 resection. At present, the ability to perform a complete resection with negative margins is limited by the surgeon's ability to palpate and visualize the tumor and its margins. Therefore, in order to reduce operative morbidity and costs while maintaining or improving surgical and oncologic outcomes, the investigators must develop technologies that improve visualization of the primary tumor and occult metastases, real time, during surgery. Recent research has demonstrated that the use of fluorescent probes that recognize cancer specific antigens can be used for this purpose when visualized using a prototype near-infrared multispectral imaging system.

This investigation will determine if folate-FITC, a fluorescent probe that recognizes the folate receptor (present in > 90% of ovarian cancers) can facilitate surgical resection and detect tumor nodules not visible to the naked eye.

View Eligibility Criteria

Eligibility Criteria

Inclusion Criteria:

Women who are:

Diagnosed with or at high clinical suspicion of primary ovarian cancer by either radiologic imaging or physical examination or biopsy or serum tumor markers
Scheduled to undergo surgical cytoreduction via laparotomy
At least 18 years of age
Capable and willing to provide informed consent

Exclusion Criteria:

Women with:

Known sarcomatous histologies
Recurrent ovarian cancer
Planned surgical approach via laparoscopy or robotic surgery
A history of anaphylactic reactions to Folate-FITC or insects
Inability or unwillingness to provide informed consent

Study is for people with:

Ovarian Cancer

Phase:

Phase 2

Estimated Enrollment:

27

Study ID:

NCT01511055

Recruitment Status:

Terminated

Sponsor:

Mayo Clinic

Check Your Eligibility

Let’s see if you might be eligible for this study.

What is your age and gender ?

Submit

There is 1 Location for this study

See Locations Near You

Mayo Clinic
Rochester Minnesota, 55905, United States

How clear is this clinincal trial information?

Study is for people with:

Ovarian Cancer

Phase:

Phase 2

Estimated Enrollment:

27

Study ID:

NCT01511055

Recruitment Status:

Terminated

Sponsor:


Mayo Clinic

How clear is this clinincal trial information?

×

Introducing, the Journey Bar

Use this bar to access information about the steps in your cancer journey.

Please confirm you are a US based health care provider:

Yes, I am a health care Provider No, I am not a health care provider